These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1094 related articles for article (PubMed ID: 471128)

  • 1. Histologic changes in the human skin melanoma after intratumorous treatment with BCG.
    Svejda J; Mechl Z; Sopková B; Foukal T
    Neoplasma; 1979; 26(2):215-21. PubMed ID: 471128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
    Korting HC; Strasser S; Konz B
    Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
    Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
    Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
    Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 9. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of the complications occurring in BCG vaccine immunotherapy of patients with malignant neoplasms].
    Grigorovich NA; Risina DIa; Nodel'son SE
    Vopr Onkol; 1984; 30(7):102-6. PubMed ID: 6464396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L; Gorgone S; Palmeri R; Salibra M; Melita P
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intrafocal BCG therapy of metastasizing malignant melanoma].
    Kunze J; Lesch R; Plagwitz R; Hagedorn M
    Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 17. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cell-mediated BCG-diagnosis using a multipuncture apparatus in melanoma].
    Wolf M
    Dermatol Monatsschr; 1976 Sep; 162(9):756-7. PubMed ID: 992184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 55.